• LAST PRICE
    26.9920
  • TODAY'S CHANGE (%)
    Trending Up0.7920 (3.0229%)
  • Bid / Lots
    26.7800/ 1
  • Ask / Lots
    27.5000/ 2
  • Open / Previous Close
    26.2200 / 26.2000
  • Day Range
    Low 26.2200
    High 27.1900
  • 52 Week Range
    Low 12.0800
    High 62.0750
  • Volume
    8,613
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 26.2
TimeVolumeBCYC
09:32 ET483826.88
09:34 ET89027.19
09:36 ET120027.04
09:39 ET25026.992
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBCYC
Bicycle Therapeutics PLC
776.8M
-8.9x
---
United StatesACET
Adicet Bio Inc
749.7M
-16.6x
---
United StatesPMVP
PMV Pharmaceuticals Inc
777.0M
-11.9x
---
United StatesNUVL
Nuvalent Inc
777.4M
-9.6x
---
United StatesRLMD
Relmada Therapeutics Inc
785.2M
-3.7x
---
United StatesBLTE
Belite Bio Inc
755.2M
-78.8x
---
As of 2022-08-08

Company Information

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist. The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Contact Information

Headquarters
Babraham HallCAMBRIDGE, United Kingdom CB21 6GS
Phone
122-326-1503
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$776.8M
Revenue (TTM)
$16.3M
Shares Outstanding
29.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.04
Book Value
$11.71
P/E Ratio
-8.9x
Price/Sales (TTM)
47.5
Price/Cash Flow (TTM)
---
Operating Margin
-532.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.